Eyeing Up Success in Fill/Finish
Certain therapeutics, such as ophthalmics, must be provided as a sterile dosage form but can pose fill/finish challenges due to the small batch sizes required and the fact that the products used are difficult to fill and of high value.
Sterile fill/finish manufacturing is expected to experience significant growth over the coming years, with some market research analysts predicting the field to be worth $12.1 billion by 2025 (1). Expanded drug development pipelines, incorporating more complex, large-molecule products and therapies that require sterile production, form part of the driving force for this rising demand for fill/finish services.
Ophthalmic therapeutics, in particular, require heightened expertise due to the fact that they are administered to the eyes, which are extremely sensitive and important organs. To learn more about the intricacies of sterile fill/finish manufacturing, specifically pertaining to ophthalmics, Pharmaceutical Technology spoke with Daniel Kehl, chief executive officer at swissfillon—a fill/finish specialist based in Switzerland.
Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing May 2021 eBook.
About the Author
Felicity Thomas is the European editor for Pharmaceutical Technology Group.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2021
May 2021
Pages: 49–53
Citation
When referring to this article, please cite it as F. Thomas, “Eyeing Up Success in Fill/Finish,” Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
